The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,028,226 in first-year total cost, median $297,917.
Most frequent study sections
- Special Emphasis Panel[ZAI1 AWA-M (M1)]1
- Special Emphasis Panel[ZAI1 AWA-M (M2)]1
- Special Emphasis Panel[ZAI1 LP-I (S2)]1
- Special Emphasis Panel[ZAI1 MSA-M (J1)]1
- Special Emphasis Panel[ZAI1 PT-I (M2)]1
Most frequent institutions
- CARTESIAN THERAPEUTICS, INC.1
- MOONLIGHT THERAPEUTICS, INC.1
- SANARIA, INC.1
- TRELLIS BIOSCIENCE, INC.1
- TSRL, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Bacterial Pneumonia Therapeutic Antibody Safety Trial1U44AI183920-01 | KAUVAR, LAWRENCE MICHAEL | TRELLIS BIOSCIENCE, INC., CA | $297,917 | ZAI1 |
| 2024 | Phase 1 Clinical Trial to Assess the Pharmacokinetics, Safety and Tolerance of a Zanamivir Transdermal System in Healthy Subjects1U44AI184201-01 | LIPKA, ELKE | TSRL, INC., MI | $292,746 | ZAI1 |
| 2024 | Targeting BCMA+ Cells with RNA-engineered CAR T cells to treat Lupus: A Phase 2 clinical study1U44AI184200-01 | JEWELL, CHRISTOPHER M | CARTESIAN THERAPEUTICS, INC., MD | $149,008 | ZAI1 |
| 2023 | Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin) patch for the Treatment of Peanut Allergy1U44AI165328-01A1 | PATEL, SAMIRKUMAR | MOONLIGHT THERAPEUTICS, INC., GA | $299,783 | ZAI1 |
| 2022 | PfSPZ Vaccine for Prevention of Plasmodium falciparum malaria1U44AI167783-01 | HOFFMAN, STEPHEN LEV | SANARIA, INC., MD | $988,772 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.